Latest Research Confirms Glycans as Aging Biomarkers with Therapeutic Plasma Exchange Benefits

Validating Glycans: A New Era in Aging Biomarkers

Recent findings from GlycanAge and Circulate Health have illuminated a groundbreaking connection between IgG glycans and biological age assessment. A comprehensive study, integrating data from over 20,000 individuals across 42 studies, has established that IgG glycans are not just indicators of biological age but can also be modified through interventions like therapeutic plasma exchange (TPE). This remarkable research, led by Professor Gordan Lauc, marks the most extensive analysis to date on IgG glycosylation, paving the way for new approaches in longevity science.

An Insight into the Research

The study titled The Immunoglobulin G Glycome: A Modifiable Biomarker and Functional Effector of Aging, Disease, and Mortality, evaluates the glycosylation of immunoglobulin G (IgG) and its potential impact on aging, chronic illnesses, and overall mortality. It is the first to analyze both glycan aging, and disease responsiveness to interventions, placing them in a singular analytical framework.

Among the numerous findings, the research emphasizes the IgG glycome’s predictive abilities regarding all-cause mortality, showcasing its responsiveness to therapeutic changes. Specifically, the study highlights three effective interventions: TPE, hormone replacement therapy (HRT), and caloric restriction, where TPE demonstrated the most noticeable effects in reducing glycan patterns.

The Impact of Therapeutic Plasma Exchange

Therapeutic plasma exchange, traditionally utilized over the past 50 years in treating autoimmune and hematological disorders, has seen increased scrutiny regarding its efficacy in extending healthspan. Recent trials, particularly by Circulate Health in partnership with the Buck Institute, showcase that biweekly TPE treatments, coupled with intravenous immunoglobulin (IVIG) therapy, can reduce biological age by an impressive average of 2.6 years. With additional preprint research confirming that monthly TPE sessions yield a reduction of 0.4 years per month in glycan age, the evidence is building for TPE as a valid intervention in the realm of aging research.

Professor Gordan Lauc, a critical figure in this study and Chief Scientific Officer at GlycanAge, articulated the unique position this research holds in the longevity sector. He notes, “Many interventions in the longevity area lack clinical validation. However, therapeutic plasma exchange stands out because it has been systematically researched, providing measurable biological impacts.” Upon assessing IgG glycosylation, researchers can closely monitor the influence of TPE on chronic inflammation and immune aging, offering an invaluable tool for evaluating clinical applications.

Looking Ahead: The Future of Longevity Science

The implications of this research are vast. As Eric Verdin, co-founder of Circulate Health, states, “This is an exciting time for longevity science, where mechanistic insights from laboratories translate into concrete improvements in patient health.” The integration of rigorous clinical evaluations ensures the accuracy and reliability of the findings, gradually transitioning the field towards an evidence-based approach for enhancing health spans.

The findings also fulfill the stringent criteria established by the Biomarkers of Aging Consortium, which includes mechanistic grounding in aging hallmarks, predictive validity for clinical outcomes, and responsiveness to detectable geroprotective interventions.

As GlycanAge and Circulate Health continue to explore the intersections of biology and aging, the future looks promising. With a push towards glycan-based diagnostics and therapies, there is hope for more tailored and effective healthspan-extension interventions in clinical settings.

In conclusion, this landmark study not only validates glycans as significant aging biomarkers but also underscores the potential of established therapies like TPE in combating biological aging—ushering in a fresh perspective on longevity and health. For more insights into these findings, reach out to Dr. Ana Cvetko at GlycanAge.